De-risking represents a relatively new but developing strategy designed to quickly assess if a new drug has a liability. Knowing your compound’s risk for drug-to-drug interactions (DDI), drug induced liver injury (DILI) and metabolites in safety testing (MIST) early on in drug development, leads to greater confidence and added value on your molecule’s journey to market.
This free webinar, hosted by Guy Webber (Scientific Manager – in vitro and drug-to-drug interactions), is ideal for those companies with small molecules or biologic compounds in any stage of drug discovery and development.
Register for this webinar to:
- Discover the three major risks leading to non-approval, delay and withdrawal from the market
- Understand when each of these three risks occur
- Learn how to de-risk your drug against DDI, DILI and MIST
- Realize the true value of de-risking your molecule
Register today for the 45 minute ‘De-risking drug development: in vitro strategies that add value to your molecule’ webinar and learn:
- What is de-risking?
- What are the three major risks leading to non-approval, delay and withdrawal from the market?
- When do these risks occur?
- How do you mitigate your molecule’s exposure to these risks?
- How does de-risking actually add value to your drug?
- And much more
Promising combination therapy could improve liver cancer outcomes